Know Cancer

or
forgot password

The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature


N/A
18 Years
N/A
Not Enrolling
Both
Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature


OBJECTIVES:

- Evaluate the ability of positron emission tomography (PET) to assess the effect of
therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume
in patients enrolled on a treatment protocol evaluating a therapeutic modality
effecting the tumor associated vasculature.

- Evaluate the ability of PET to assess the effects of this type of therapy regimen on
tumor uptake of fluorodeoxyglucose in these patients.

- Evaluate the ability of magnetic resonance imaging (MRI) to assess the effects of
therapy directed against the tumor vasculature on tumor blood flow and tumor vascular
density in these patients.

- Compare the findings on PET and/or MRI with those obtained from conventional CT in this
patient population.

OUTLINE: This is a diagnostic study conducted concurrently with a therapeutic modality
study.

Patients have magnetic resonance imaging and/or positron emission tomography (PET) scans
performed prior to start of therapy, 6 weeks and 16 weeks following the initiation of
therapy, and 6 weeks following the completion of therapy. Each scan requires about 1-3
hours. Patients receive up to 3 different PET scans including tumor blood flow scan with
H2015, tumor blood volume scan with 11CO, and glucose uptake scan with fludeoxyglucose F 18.

PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 2 years.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Eligible for a treatment protocol evaluating a therapeutic modality that may have an
effect on tumor associated vasculature

- Measurable or evaluable disease by standard CT or MRI

- At least 1 lesion measuring greater than 2 cm in diameter

PATIENT CHARACTERISTICS:

Age:

- Over 18

Performance status:

- Not specified

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Creatinine no greater than 2.0 mg/dL

Other:

- Not pregnant or nursing

- Negative pregnancy test

- No pacemakers, aneurysm clips, shrapnel injury, or implantable electronic devices

- Weight no greater than 136 kilograms

- No sensitivity to contrast agents that cannot be controlled with premedication

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified

Type of Study:

Interventional

Study Design:

Primary Purpose: Diagnostic

Principal Investigator

Steven K. Libutti, MD

Investigator Role:

Study Chair

Investigator Affiliation:

NCI - Surgery Branch

Authority:

United States: Food and Drug Administration

Study ID:

980163

NCT ID:

NCT00019565

Start Date:

October 1998

Completion Date:

Related Keywords:

  • Unspecified Adult Solid Tumor, Protocol Specific
  • unspecified adult solid tumor, protocol specific

Name

Location

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesda, Maryland  20892-1182